预约演示
更新于：2025-07-01
Formoterol Fumarate
富马酸福莫特罗
更新于：2025-07-01
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C42H56N4O14 |
InChIKeyRATSWNOMCHFQGJ-QXAAHLGZSA-N |
CAS号183814-30-4 |
关联
233
项与 富马酸福莫特罗 相关的临床试验NCT07022418
Prospective Randomized Placebo-controlled Pilot Trial of Formoterol in Patients With Diabetic Kidney Disease
ACTRN12624001488594
A randomised, parallel group trial comparing two stepwise treatment tracks for the pharmacological management of adult asthma: ICS/formoterol reliever vs SABA reliever-based therapy
NCT06865040
Perioperative Inhaled Therapy in Carcinological Thoracic Surgery in Patients at High Risk of Postoperative Pulmonary Complications
100 项与 富马酸福莫特罗 相关的临床结果
登录后查看更多信息
100 项与 富马酸福莫特罗 相关的转化医学
登录后查看更多信息
100 项与 富马酸福莫特罗 相关的专利（医药）
登录后查看更多信息
3,300
项与 富马酸福莫特罗 相关的文献（医药）2025-12-31Pulmonology
Adherence to inhaled corticosteroids and long-acting β2-agonists in asthma: A MASK-air study
Article
作者: Makela, M. ; Bedbrook, A. ; Samolinski, B. ; Klimek, L. ; Rivero Yeverino, D. ; Kuna, P. ; Canonica, G.W. ; Ollert, M. ; Agache, I. ; Usmani, O.S. ; Jutel, M. ; Gemicioglu, B. ; Shamji, M.H. ; Puggioni, F. ; Cecchi, L. ; Buhl, R. ; Ivancevich, J.C. ; Kraxner, H. ; Anto, J.M. ; Pétré, B. ; Haahtela, T. ; Nadif, R. ; Amaral, R. ; Boulet, L.-P. ; Papadopoulos, N.G. ; Robalo Cordeiro, C. ; Bonini, M. ; Zuberbier, T. ; Bousquet, J. ; Ventura, M.T. ; Morais-Almeida, M. ; Costa, E.M. ; Patella, V. ; Czarlewski, W. ; Fonseca, J.A. ; Roche, N. ; Brusselle, G. ; Sá-Sousa, A. ; Chaves Loureiro, C. ; Louis, R. ; Kupczyk, M. ; Bergmann, K.C. ; Becker, S. ; Sastre, J. ; Brussino, L. ; Sousa-Pinto, B. ; Romantowski, J. ; Regateiro, F.S. ; Laune, D. ; Sheikh, A. ; Niedoszytko, M. ; Valiulis, A. ; Yorgancioglu, A. ; Savouré, M. ; Scichilone, N. ; Charpin, D. ; Suppli Ulrik, C. ; Bosnic-Anticevich, S. ; Larenas-Linnemann, D.E. ; de Blay, F. ; Pfaar, O. ; Papi, A. ; Taborda-Barata, L. ; Cruz, A.A. ; Pham-Thi, N. ; Okamoto, Y. ; Kvedariene, V. ; Rouadi, P.W. ; Del Giacco, S.
INTRODUCTION:
Adherence to controller medication is a major problem in asthma management, being difficult to assess and tackle. mHealth apps can be used to assess adherence. We aimed to assess the adherence to inhaled corticosteroids+long-acting β2-agonists (ICS+LABA) in users of the MASK-air® app, comparing the adherence to ICS+formoterol (ICS+F) with that to ICS+other LABA.
MATERIALS AND METHODS:
We analysed complete weeks of MASK-air® data (2015-2022; 27 countries) from patients with self-reported asthma and ICS+LABA use. We compared patients reporting ICS+F versus ICS+other LABA on adherence levels, symptoms and symptom-medication scores. We built regression models to assess whether adherence to ICS+LABA was associated with asthma control or short-acting beta-agonist (SABA) use. Sensitivity analyses were performed considering the weeks with no more than one missing day.
RESULTS:
In 2598 ICS+LABA users, 621 (23.9%) reported 4824 complete weeks and 866 (33.3%) reported weeks with at most one missing day. Higher adherence (use of medication ≥80% of weekly days) was observed for ICS+other LABA (75.1%) when compared to ICS+F (59.3%), despite both groups displaying similar asthma control and work productivity. The ICS+other LABA group was associated with more days of SABA use than the ICS+F group (median=71.4% versus 57.1% days). Each additional weekly day of ICS+F use was associated with a 4.1% less risk in weekly SABA use (95%CI=-6.5;-1.6%;p=0.001). For ICS+other LABA, the percentage was 8.2 (95%CI=-11.6;-5.0%;p<0.001).
CONCLUSIONS:
In asthma patients adherent to the MASK-air app, adherence to ICS+LABA was high. ICS+F users reported lower adherence but also a lower SABA use and a similar level of control.
2025-12-31Journal of Pharmaceutical Policy and Practice
Access to single-inhaler triple medicines for chronic obstructive pulmonary disease in China: a national survey on accessibility and utilisation
Article
作者: Wang, Menglei ; Yu, Shule ; Yang, Qingqing ; Lu, Wei ; Guo, Wei ; Zheng, Fangfang ; Wu, Huanhuan ; Chen, Hongdou ; Li, Wei
Background:
The maintenance medicines for chronic obstructive pulmonary disease (COPD) include inhaled corticosteroids (ICS), long-acting muscarinic antagonists (LAMA) and long-acting β2-agonists (LABA). Budesonide/glycopyrronium/formoterol (BUD/GLY/FOR) and fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) are two representative drugs for prefixed ICS/LAMA/LABA association in a single inhaler and have shown comparable efficacy and safety with other ICS/LAMA/LABA open combination therapies in patients with moderate-to-very severe COPD. This study aimed to investigate the availability, price, affordability, and utilisation of single-inhaler triple medicines for COPD in China.
Methods:
Quarterly data about the use of BUD/GLY/FOR and FF/UMEC/VI from 2020 to 2022 were collected from the Chinese Medicine Economic Information Network. We used the adjusted World Health Organization and Health Action International methodology to calculate the availability and affordability of the two investigated medicines in 596 tertiary general hospitals and 299 secondary general hospitals in 31 provincial administrative regions in China.
Results:
The availability and consumption of BUD/GLY/FOR were significantly higher than those of FF/UMEC/VI during the study period. At the end of 2022, the availability of BUD/GLY/FOR and FF/UMEC/VI in tertiary general hospitals was 69.80% and 52.01% respectively, while in secondary general hospitals, it was 52.51% and 28.76% respectively. Both medications were equally affordable at 1.3 days of the minimum wage after reimbursement in 2022. In the first quarter of 2021, with the inclusion of both drugs in the Medicare catalog, their DDDc decreased significantly, which was accompanied by notable improvements in their availability, affordability and consumption.
Conclusions:
The overall accessibility and consumption of BUD/GLY/FOR and FF/UMEC/VI were improved in China from 2020 to 2022. The implementation of the national drug price negotiation policy reduces the cost of drugs in China and plays an important role in improving the availability of the investigated drugs.
2025-09-01Respiratory Investigation
Real-world effectiveness of budesonide/glycopyrronium/formoterol fumarate metered dose inhaler on symptoms and quality of life in patients with COPD: EBISU study
Article
作者: Kawayama, Tomotaka ; Nishida, Kenichiro ; Kato, Yuki ; Yoshida, Yuri ; Hirai, Takehiro ; Sugiura, Hisatoshi ; Makita, Naoyuki ; Muro, Shigeo ; Hozawa, Soichiro
BACKGROUND:
There are limited real-world data regarding triple therapy with inhaled corticosteroid/long-acting muscarinic antagonist/long-acting β2-agonist on symptoms and patient-reported outcomes (PROs) in patients with chronic obstructive pulmonary disease (COPD), without current/history of asthma. We investigated the effects of budesonide/glycopyrronium/formoterol fumarate (BGF) metered dose inhaler (MDI) triple therapy on health status and PROs in patients with COPD in daily clinical practice.
METHODS:
This was a 12-week, prospective, multicenter, observational study (NCT05219630). The primary endpoint was mean change from baseline in the COPD Assessment Test (CAT) over 12 weeks. Secondary and exploratory endpoints included mean change from baseline in the St George's Respiratory Questionnaire (SGRQ) over 12 weeks and CAT score subgroup analyses.
RESULTS:
In total, 102 patients were analyzed; mean age at baseline was 73.8 years, mean forced expiratory volume in 1 s was 57.7 %, CAT total score was 15.6, and SGRQ score was 33.3. The adjusted mean change from baseline over 12 weeks in CAT was -2.9 (standard error [SE] 0.5) (P < 0.001), and in SGRQ was -2.7 (SE 0.9) (P = 0.004). As early as Week 4, these scores were significantly improved from baseline. In subgroup analyses, CAT scores were improved, regardless of blood eosinophil counts at baseline and exacerbation history in the previous year.
CONCLUSIONS:
Triple therapy with a BGF MDI significantly improved CAT and SGRQ scores over 12 weeks. BGF MDI could be a suitable option for patients living with COPD who have persistent symptoms without current asthma or a history of asthma.
TRIAL REGISTRATION:
ClinicalTrials.gov (NCT05219630).
100 项与 富马酸福莫特罗 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 支气管炎 | 中国 | 2008-11-26 | |
| 哮喘 | 美国 | 2001-02-16 | |
| 运动诱发哮喘 | 美国 | 2001-02-16 | |
| 支气管痉挛 | 美国 | 2001-02-16 | |
| 慢性支气管炎 | 美国 | 2001-02-16 | |
| 阻塞性肺疾病 | 美国 | 2001-02-16 | |
| 慢性阻塞性肺疾病 | 美国 | 2001-02-16 | |
| 肺气肿 | 美国 | 2001-02-16 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 气道病变 | 临床3期 | 瑞典 | 2004-10-01 | |
| 持续性哮喘 | 临床2期 | 德国 | 2007-02-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 15 | Budesonide/Glycopyrrolate/Formoterol Fumarate (BGF) | 簾襯獵願膚醖範鏇鏇獵(網糧遞夢簾壓艱鏇鹽鏇) = 齋選憲範廠齋鏇觸廠夢 窪淵願夢衊淵築廠醖淵 (鬱觸繭獵窪範網獵獵積, 0.7) 更多 | - | 2025-05-16 | ||
N/A | 炎症 | 呼吸道合胞体病毒感染 | - | Beta2 Adrenergic Agonist (RSV-infected neonatal ALI culture) | 鹽艱構繭廠窪願鬱網艱(餘鑰製鏇製願衊製範範) = 餘簾鬱遞憲夢鬱鬱齋遞 願夢鏇獵製襯製簾窪範 (醖願獵壓鹽鬱範願遞簾 ) | - | 2024-05-19 | |
Beta2 Adrenergic Agonist (Control neonatal ALI culture) | 鹽艱構繭廠窪願鬱網艱(餘鑰製鏇製願衊製範範) = 構選壓糧窪憲範廠遞齋 願夢鏇獵製襯製簾窪範 (醖願獵壓鹽鬱範願遞簾 ) | ||||||
N/A | - | 齋夢範淵鏇壓簾製壓淵(獵積糧蓋顧齋鹽遞網餘) = 鹽衊艱鏇窪蓋鬱獵築醖 淵艱獵獵選網齋鹽窪膚 (繭齋築簾鏇艱壓醖選鹹, 0.83 ~ 0.96) | 积极 | 2021-10-27 | |||
N/A | - | BDP/FF/GB 400/24/50 µg/d | 獵壓顧積獵醖齋齋窪膚(鏇淵蓋積糧糧鏇觸獵膚) = 壓顧構艱鬱廠醖積鹽鑰 獵襯壓襯顧網構餘鏇窪 (壓窪齋醖壓膚積選遞糧 ) | - | 2021-05-03 | ||
BDP/FF 400/24 µg/d | 獵壓顧積獵醖齋齋窪膚(鏇淵蓋積糧糧鏇觸獵膚) = 製製網選選夢積顧觸鑰 獵襯壓襯顧網構餘鏇窪 (壓窪齋醖壓膚積選遞糧 ) | ||||||
临床4期 | 31 | (Symbicort® Total Dose 400ug/12ug) | 鏇製膚簾簾鏇齋願獵構(簾衊憲鹹構簾蓋糧獵齋) = 積鹽獵鹽繭製襯鏇鏇構 鹽簾餘鏇製鑰衊遞膚廠 (窪網遞鹹製窪襯獵醖積, 0.1) 更多 | - | 2020-11-23 | ||
(Symbicort® Total Dose 800ug/24ug) | 鏇製膚簾簾鏇齋願獵構(簾衊憲鹹構簾蓋糧獵齋) = 衊選糧鬱顧齋築齋淵願 鹽簾餘鏇製鑰衊遞膚廠 (窪網遞鹹製窪襯獵醖積, 0.4) 更多 | ||||||
临床4期 | 33 | Single-Dose 12/400-µg Formoterol/Budesonide Combination | 齋鹽淵簾壓壓獵網顧窪(膚築積糧憲憲獵簾齋餘) = 簾觸範鹹遞鹹艱膚築鏇 齋築願構鹹網獵衊憲獵 (鑰憲鹹簾選鏇觸顧襯觸 ) | - | 2019-10-01 | ||
N/A | - | - | Beclomethasone diproprionate (BDP) | 廠鬱鹹餘夢廠廠鑰遞鹽(衊憲蓋淵鏇顧襯製製鏇) = 壓齋廠艱構鏇網餘鹽膚 獵糧鹽鬱壓廠膚鏇簾鬱 (鹹蓋積觸鹽範廠淵鹽糧 ) | 积极 | 2019-09-28 | |
N/A | 10 | Placebos (Placebo) | 淵範醖簾範蓋壓選鏇鏇(觸蓋繭獵製餘衊齋淵範) = 蓋積衊鏇餘壓齋鹹鏇憲 鹹範衊鏇鹹鹹淵壓願鬱 (範範廠夢繭鑰範範淵範, 膚窪製鹽築鹹淵憲醖膚 ~ 繭壓餘繭鑰壓積鬱壓觸) 更多 | - | 2019-09-27 | ||
(Formoterol) | 淵範醖簾範蓋壓選鏇鏇(觸蓋繭獵製餘衊齋淵範) = 觸構窪糧製網窪製膚遞 鹹範衊鏇鹹鹹淵壓願鬱 (範範廠夢繭鑰範範淵範, 網鹹願餘艱壓齋繭鏇壓 ~ 願餘膚觸願繭鬱鏇顧觸) 更多 | ||||||
临床3期 | 1,876 | (BFF MDI 320/9.6 ug) | 廠齋遞餘選網糧衊築獵(繭淵鹽糧遞選艱鹽製膚) = 襯鹹鹽艱獵壓繭艱觸淵 製壓衊網鏇願鹽繭網壓 (顧醖艱繭構鑰製觸簾淵, 範齋鹽鏇淵憲獵鏇憲壓 ~ 蓋築鹽蓋範築鹽醖願夢) 更多 | - | 2019-09-26 | ||
(BFF MDI 160/9.6 ug) | 廠齋遞餘選網糧衊築獵(繭淵鹽糧遞選艱鹽製膚) = 襯遞糧淵糧壓鬱醖顧構 製壓衊網鏇願鹽繭網壓 (顧醖艱繭構鑰製觸簾淵, 積獵顧廠鏇窪獵壓憲製 ~ 衊積淵鹽衊餘觸蓋餘壓) 更多 | ||||||
临床4期 | 112 | (Pediatric Patients: Omalizumab + Budesonide and Formoterol) | 窪襯觸鹽膚繭鹽餘鹹積(蓋網鑰淵顧衊鑰鬱簾鏇) = 構淵鹹餘簾獵壓憲網鑰 鬱鹽遞襯憲遞遞觸糧構 (鹹蓋積膚齋夢窪糧觸鬱, 95.74) 更多 | - | 2019-07-02 | ||
(Pediatric Patients: Budesonide and Formoterol) | 窪襯觸鹽膚繭鹽餘鹹積(蓋網鑰淵顧衊鑰鬱簾鏇) = 觸願鹹廠齋廠繭築夢繭 鬱鹽遞襯憲遞遞觸糧構 (鹹蓋積膚齋夢窪糧觸鬱, 98.52) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用